Gewinn- und Verlustrechnung von HCA Healthcare, Inc.

HCA is expanding hospitals, ERs and outpatient sites while investing billions in new capacity to support future healthcare demand and long-term growth.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.

HCA Healthcare highlights promising pediatric CRISPR gene therapy results as expanding specialty care and research investments support its long-term growth strategy.

NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE:HCA), one of the nation's leading healthcare providers, today announced new research published in The New England Journal of Medicine (NEJM) demonstrating promising results from a gene-editing therapy being investigated in children ages 5-11 with severe sickle cell disease and transfusion-dependent beta thalassemia. Sickle cell disease and beta thalassemia are inherited blood disorders that can cause serious, lifelong complications b.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

The May Jobs report told a familiar story for investors in healthcare stocks. The sector added 35,200 positions last month, led by ambulatory health services at 25,700 and hospitals at 6,000.

On June 10, 2026, we present a detailed DCF analysis for HCA Healthcare Inc (HCA), a company currently facing a challenging price performance context with a yea

SAN FRANCISCO--(BUSINESS WIRE)--Mission Bio, the leader in single-cell multiomics solutions, today announced a collaboration with the Human Cell Atlas (HCA), a global consortium working to create comprehensive reference maps of all human cells to advance the understanding, diagnosis, and treatment of disease. The announcement comes ahead of the upcoming Human Cell Atlas General Meeting 2026, taking place June 16–18 in Boston, where Mission Bio will participate alongside leading researchers and.